

REVIEW

# Perspectives on the enhancement of commercially available antibiotics by natural products

Lucia Nitsch-Velasquez<sup>1,2,3\*</sup>, Sara B. Barrios<sup>1,2</sup>, Ricardo A. Montoya<sup>4</sup> and Rosy Canales<sup>1</sup>

\*Correspondence:

lucianitsch@cunzac.edu.gt

<sup>1</sup>Research and Development

Department, Proyectos Educativos

Regionales de Autoayuda, Simeon

Canas Avenue 8-25a zona 2,

01002 Guatemala, Guatemala

Full list of author information is available at the end of the article

## Abstract

**Background:** Opportunistic resistant bacteria are health and economically relevant in the health care systems and in industries worldwide, especially in the so-called resistant bacteria era (RBE). Enhancing the activity of commercially available antibiotics (CAAs) with different types of natural products (NPs) is a successful antimicrobial strategy, for instance the amoxicillin and clavulanate mixture.

**Objective:** To find research trends in this field during 2015-2020 and to detect potential drug hits with potential to diversify formulations and materials design that can be useful to manage the RBE.

**Systematic review results:** It yielded 190 reports of synergistic effects of CAAs and NPs. The analyzed variables were: a) natural products origin: plant family, genera, secondary metabolite type; b) strains: +/- Gram, genera, most frequent species, application field; and c) CAAs: family, most frequent CAAs. The families with potential to have more bioactive species were *Apocynaceae*, *Rubiaceae*, *Euphorbiaceae* ( $I_{sbio}$  factor). *Lonicera* had the highest reports amount. Polyphenols and flavonoids were the majority of pure NPs tested. Several potential drug hits for antibiotic activity enhancement at synergistic level were identified together with potential mechanisms of action: berberine (drug efflux inhibitor-DEI, biofilm inhibitor-BI), curcumin (BI), essential oils (BI), 3-o-metyl-butylgallato (inhibition of fatty acid saturation), among others. About the half of the tested strains were gram positive, being Methicillin Resistant *Staphylococcus aureus* (MRSA) the most frequently tested. *Escherichia coli* was the gram negative strain most frequently reported, including enterotoxigenic and extended spectrum beta-lactamases producers. The growth of other foodborne genera strains, such as *Listeria* and *Salmonella*, were also inhibited. Aminoglycosides were the family most reported, with gentamicin as the most commonly studied.

**Conclusions:** NPs as either as plant extracts from a variety of families, or as purified compounds specially flavonoids and polyphenols, have shown effective results to enhance the antibiotic activity of CAAs against gram positive and negative strains relevant to HC and FI. Their mechanisms of action are starting to be determined, as the case EPIs and BIs. Further research is needed to achieve co-formulations and materials design useful for those fields, that can certainly be positively impacted by pursuing this strategy.

**Keywords:** synergistic effects; enhancement antibiotic activity; antibiotics; natural products; flavonoids; terpenoids; biofilm inhibitors; efflux pump inhibitors; aminoglycosides; co-formulating

## Background

Opportunistic bacteria are relevant in the health care systems and in industries that involve living organisms. For instance, in 2021 the cost of human illness caused by food borne pathogens costed more than 15.6 billion USD to USA. A 48% of those outbreaks were related to meat, and 34% were related to plant based foods. This phenomena contributes to the emergence of antibiotic-resistant bacteria which positively feed backs the increment of food borne antibiotic-resistant infections. Among the CDC and FDA, and USDA strategies to address these issues are: **a)** to stimulate the antibiotic drug discovery, **b)** to improve the appropriate antibiotic use in veterinary medicine and agriculture, and **c)** to ensure that the related industries have tools, information, and training on antibiotic use [1, 2, 3, 4, 5].

To properly manage the resistant bacteria era, humankind must advance its antimicrobial toolbox. One strategy is to enhance the activity of already commercialized antibiotics, and even to revert antibacterial resistant by co-formulating the antibiotic drugs with those enhancers. A successful example of this approach is the mixture of amoxicillin and clavulanic acid. This mixture was patented in 1985, consisting of a semi-synthetic derivative of penicillin mixed with an inhibitor of the enzyme beta-lactamase isolated from *Streptomyces clavuligerus*. The market for amoxicillin is expected to raise up to 4,256 million USD by 2026, at the same time resistant strains are emerging and antibiotic drug discovery and re-formulation is on demand (CDC) [6, 3].

Acknowledging the success of amoxicillin-clavulanate potassium combo and the relevance of the resistant bacteria in health care systems and industry, and taking in account the promise of natural products as source of bioactive compounds, a systematic literature review was performed aiming to identify potential natural products that can improve the antibiotic activity against opportunistic bacteria, with potential applications in the food industry.

## Literature Review Methods

### Literature search parameters

The literature search parameters were defined as following: **i) Databases and search engines:** National Center for Biotechnology Information (NCBI) – Pubmed Central, [7] Scifinder, [8] In the cases in which the search engine also yielded recommended articles related to the found article, follow up of such studies was performed.

**ii) Publication date:** in the range from april 2016 up to 2020 **iii) Targeted content:** Antimicrobial activity evaluation of commercially available antibiotics together with natural extracts against opportunistic microbes (CAAs and NE-OM), such that yielded synergistic effects results which data analysis included either FICI or a statistical comparison between control and test groups. Also, analog results from testing the main component(s) of any given natural extract were also included. **iv) Keywords and phrases:** The keywords applied to start the literature search in the different databases and search engines were: synergistic effects natural products and antibiotics, botanicals and antibiotics bioassays, plant extracts interaction with antibiotics, and antibiotic adjuvant bioassays. **v) Exclusion criteria:** results classified as either antagonist, additive, or non-interaction effects of CADs and NPs tests; results classified as either enhancement or modulating effects of CADs and

NPs tests, such that were reported without statistical analysis, such that it was not possible to conclude if synergistic effects were observed; only the NPs (either as extract or purified components from it) were tested for antimicrobial activity; mixture of two or more NPs, even if those yielded antimicrobial synergistic effects; mixture of two or more CADs, even if those yielded antimicrobial synergistic effects.

#### Data analysis

The selected registries were analyzed based on a set of parameters that are analyzed in the following paragraphs. In brief, first, the analysis of the origin was divided into plant extracts and type of secondary metabolite. To further analyze the extracts origin, the frequency of reported families and genus were tabulated. In order to detect potential mining taxa for either more bioactive species ( $I_{sbio}$  above 0.80 for a given family) or to define species that are the most studied ( $I_{sbio}$  below 0.3 for a given family), we proposed and utilized the  $I_{sbio}$  index for further analysis (see Fig. 1).

Then, the tested bacteria were analyzed by strain, gram positive or negative, and field of relevance. The antibiotics that rendered synergistic effects were grouped by their type. Additionally, the natural products that yielded antibiofilm inhibition activity were compiled.

## Results and Discussion

A succinct summary is shown in Fig. 3 and the prisma escheme for the literature review in Fig. 1. A total of 270 reports of synergistic effects of natural products and commercially available antibiotics (Syn-NPs-CAAs) were retrieved, together with several reviews on the topic [9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25].

The Syn-NPs-CAAs were referred as a combinatory therapy [26], Chinese medicine and Western medicine integration [27], and an hybrid combination [15], all of them highlighting the fact of the utilization of an already validated commercially available antibiotic and a natural product that has not yet been validated by the same means, but that is known to be active in traditional medicine. Such a natural product can range from a pure compound, to fractionated extracts of a given species, to a mixture of extracts from several species.

The Syn-NPs-CAAs approach may be useful in the food industry for design of new packaging or for switching bacteria control to this hybrid formulation[15]. The synergistic effects were observed in studies with slightly variants regarding study focus, these are commented accordingly in the text.

The selected registries were analyzed based on a set of parameters that are analyzed in the following paragraphs. In brief, first, the analysis of the origin and type of natural product is presented in Sec. , also in Figs. 4, 4, and 2, and Table 4 . Then, the tested bacteria were analyzed by gram positive or negative, strain, and field of relevance, and field, see Sec. and 5. The antibiotics that rendered synergistic effects were grouped by their type are shown in Fig. 5. Additionally, the natural products that yielded antibiofilm inhibition activity (Sec. ) were compiled in Figs. 2 and 1. The chapter closes with remarks and future prospects for research, Sec. , development and innovation utilizing natural products as enhancers of antibiotic activity of CAAs.

### Origin and type of the natural products

The species studied covered from edible plants, those used in traditional medicine, up to weeds. The genera *Lonicera* (Caprifoliaceae) was reported more frequently, being almost the only genera explored in that family, notice the  $I_{sbio}$  of 0.28, see Fig. 4 and 4. Green tea *Camelia sinensis* (Theaceae) and *Aloe vera* (Xanthorrhoeaceae) are the most studied species of their respective families, and it seems as no other species are currently under the radar of synergistic effects research ( $I_{sbio}$  below 0.20).

According to an  $I_{sbio}$  above 0.80, see Fig. 4, among the families of interest due to their potential to find bioactive species are Apocynaceae, Euphorbiaceae, Malvaceae and Rubiaceae [22]. The Compositae family is also of interest to explore more species, even though its current  $I_{sbio}$  is 0.68. Compositae is one of the largest among the plant families, actually is the major group of flowering plants, with more than 27,000 known species [28].

A total of 290 assays of secondary metabolites yielded synergistic interactions with CAAs against opportunistic bacteria, some examples are given in 4 and 1. Their distribution by secondary metabolite type is shown in Fig. 2. Flavonoids and phenolics represented the majority of the tested purified extracts. The flavonoids and polyphenols families may play an important role increasing the antibiotic bioavailability, and might become relevant in hybrid formulations and materials design, *e.g.*, with CAAs [29, 30, 31, 32, 33].

Terpenoids as merulinic acid and a ursolic acid glycoside, among others, damaged the bacterial cell wall [34, 35]. Berberine can be considered a drug lead for efflux pump inhibition, such as berberine, zeylenol and bulgecin A, see Table 4 and references therein. Currently, berberine main limitation is its low bioavailability in the body [36, 37, 38, 39, 40, 32, 41, 42].

Other examples of efflux pump inhibitors are sophoroflavone G, jatrorrhizine, isovaleryl shikonin, griseviridin, 2-(2-aminophenyl)indole, flavonoids, essential oils and several plant extracts. It should be mentioned that both berberine and jatrorrhizine have also been isolated from *Mahonia bealei*, together with a variety of other alkaloids, terpenoids and polyphenols, and synergistic interactions with CAAs can be an expected result [43, 44, 45, 46, 47, 48, 40, 49, 50, 51, 52, 53].

### Strains

The mixture of NPs and CAAs were effective against strains which distribution is presented in Fig. 5. Opportunistic bacterial strains were the center of the Fractional Inhibitory Concentration Index—FICI assays. FICI was determined applying the checkerboard method (except for at least five studies that compared statistical difference by *p* value). Among the bioactivities assayed were minimal inhibitory concentration, time kill assay, and biofilm inhibitory concentration. The origin of the strains included ATCC with a variety of resistant genes and other commercially available sources, as well as clinical isolates. First line antibiotics were commonly explored, see Fig. 5, with aminoglycosides being majority.

The most frequently reported genera was *Staphylococcus*, mostly *S. aureus* (SA) and MRSA. The other two main strains were the gram negative *Escherichia coli* (EC), including ESBL-producing EC and enterotoxigenic EC, and *Pseudomonas*



*aeruginosa* (PA) including MDR variants. MRSA is in the WHO list of High Priority Bacteria that requires research and development of new antibiotics [54], and the CDC classifies MRSA as Serious Threat Level [55]. In 2014, MRSA was included among the *US government National Targets for Combating Antibiotic-Resistant Bacteria*, aiming to reduce by half (to—at least—50%) the bloodstream infections caused by MRSA [56]. Several of the studied strains belong to the so-called ES-KAPE pathogens species (**E***nterococcus faecium*, **S***taphylococcus aureus*, **K***lebsiella pneumoniae*, **A***cinetobacter baumannii*, **P***seudomonas aeruginosa*, **E***nterobacter*), a set of antibiotic-resistant pathogenic bacteria that represents new paradigms regarding pathogenesis, transmission, and resistance [57].

A set of 35 studies were focused in the type of infections more than its in the causal agent, for instance foodborne and oral infections, and those related to chronic inflammatory diseases, and veterinary, especially poultry and livestock [58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84].

The growth of foodborne strains *Listeria* sp., *Salmonella* sp., *Vibrio* sp., *Shigella* sp. was inhibited by a variety of NPs-CAAs, including essential oils such as thymol and nerolidol [85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 31, 95, 96, 27, 97, 98, 48, 40, 99, 100, 101, 102, 103, 104, 105, 106, 107, 70, 108, 86].

Oral infections caused by opportunistic bacteria are an active target for drug discovery, including the virulent factors modulation such as the biofilm formation (see below Sec. ) and a set of mouthwashes and toothpastes formulations had been patented [25, 53, 109, 110, 111, 112, 113, 114, 115, 24].

Another target, at bioassay level, was the gut microbiota regulation through the intake of selected probiotics [116].

Inhibition of the growth of gram negative bacteria represented the half of the reported strains, including MDR variants. Examples of natural products inhibiting EC, KP, and PA can be found in Fig. 4. Edible properties are relevant, especially for safety concerns on utilizing plant extracts. An example of the 49 Syn-NPs-CAAs for EC is the methanolic extracts of edible plants *Psidium guajava* L., *Persea americana* Mill., *Camellia sinensis* L., *Mangifera indica* L., *Coula edulis* Baill., and *Citrus sinensis* L. [93]. Other plant extracts inhibited EC growth with focus on foodborne, hospital acquired infections and veterinary [117, 86, 29, 118, 119, 120, 30, 121, 122, 27, 123, 124, 100, 125, 126, 127, 128, 129, 92, 130, 48, 131, 132, 93, 133, 134, 135, 136, 137, 138, 99, 139, 93, 140, 141, 142, 143, 144, 95, 89, 145, 146, 147, 78, 80, 81, 82, 93].

#### Inhibition of Toxin Production and Antibiofilm Activities

Among the reported mechanisms of action that renders synergistic effects of NPs and CAAs are the interaction of NPs with bacteria virulent factors. Which included inhibition of toxin production, biofilm formation, interference with quorum sensing molecules, inhibition of penicillin binding proteins, pump efflux inhibitors and pore forming compounds [148, 149, 150, 151, 49, 152, 50, 34, 35].

Essential oils and flavonoids are among the set of drug hits for inhibiting enterotoxin production *in vitro*. Certain polyphenols inhibited the production of enterotoxins by *S. aureus* MDR [103]. And 5-Hydroxy-3,7,4'-trimethoxyflavone inhibited the enterotoxin production by *E. coli* [141, 120]. The extract of *Spondias mombin* L. (Anacardiaceae) leaves also enhanced the amoxicillin effect against enterotoxic

EC strains, and further research may also lead other drug hits for this activity [141]. Further research on these natural products may lead to improve therapies to treat hemorrhagic diarrhea infections that are of high relevance in lower income countries [2].

Biofilm has been identified as a critical point for foodborne bacteria, as they are related to harbor variants that are resistant to antibiotics and cleaning products [4]. Antibiofilm activity was specifically reported, and usually detected with ethidium bromide assay or electron microscopy [50, 153]. The plant extracts that inhibited biofilm formation are listed in Table 2. For instance, the essential oils from the weed *Mikania cordifolia*, especially limonene, enhanced the CAAs activity against foodborne bacteria, probably via biofilm formation inhibition [89]. Specific polyphenols, alkaloids and terpenoids have also inhibited biofilm formation, see Table 1. They can be envisioned as drug hits for antibiofilm activity [154, 155, 36, 156, 157, 158, 159, 160, 161].

The presumptive drug target of MRSA biofilm is dehydroxysqualene synthase which produces staphyloxanthin, its main biofilm component [162, 163, 164, 53, 115].

Essential oils are also used to treat infections against gram negative bacteria relevant in veterinary in the Syn-NPs-CAAs format [5]. Limonene and other essential oils, as in Table 1, may be obtained by green extraction methods, they evaporate with time, and they can be detected by electronic noses, which can facilitate quality control in the food industry. Other type of components could be also included in antimicrobial formulations or in the design of plastic polymers that allow for virulence factors modulation [15, 165, 89, 121, 166, 148].

### Increasing Bioavailability and Stimulation of the Host's Immune System

Several studies using host-pathogen models reported that the enhancement of the antibiotic activity was related to the host's metabolism, *e.g.*, stimulation of the immune system or increasing bioavailability. Beyond whole one type cells assays, rodent animal models and mammalian cultured cells allows for detection of such interactions [29, 30, 31, 32, 167, 33, 168, 169, 94, 122, 170].

Those findings highlights the importance of this type of experiments to detect the induction of favorable host-pathogen interactions, at same time highlights the need to access and to develop high-through-put protocols that do not necessarily involves animals but that still can be a probe for those interactions.

### Techniques, Methods and Approaches

Several approaches and techniques are being developed in order to find antibiotic enhancers. Efforts toward rationale design drug discovery are ongoing, such as natural products inspired fragment based approach [171] and SARS studies [172]. And non-targeted mass spectrometry analyses [173] and other metabolomic based methods (biochemometric) [42] are among several platforms for high-through-put bioassays are being proposed [174, 175, 176, 161, 177].

If plant extracts are going to be used as the commercial formulation, their quality control is a key stone for its success. Dettweiler *et al.*, proposed the Extract Fractional Inhibitory Index—EFICI as quality control method of the extract, testing the actual bioactivity of the extract instead of its main components [178].

### Raw materials

Examples of research lines related to circular economy are the synergistic effects of CADs with olive leaf phenols [127], essential oil of melon peel [99], anthocyanins from wine by-products [179], and with metabolites from tobacco waste [180], fruit waste material [99].

Nutrient additives for animals food and soil fertilizers based on plant extracts are attracting interest, they not necessarily contain CADs, but their application eventually leads to reducing the amount of CADs utilized. In the case of animal feed additives. They stimulate the immune system thus potentially reducing the impact of infections and amount of CADs applied. For the case of fertilizers, they not only enrich the soil's nutrient composition but they can improve the soil's microbiota for further crop planting [94, 181, 106, 182, 183, 184, 185].

Another approach is the derivatization of natural products by linking them with other privileged scaffolds to improve their potency and ADME properties. For instance, azole derivatives carvacrol and naphthoquinones have been effective *in vitro* against gram positive and negative strains [146] and curcumin derivatives have been prepared aiming to improve their bioavailability [186].

## Conclusions and Final Remarks

Future work would involve to study more natural products and to develop materials that contain antibiotic enhancers. For example: **a)** to investigate more species and to characterize their extracts; **b)** to expand the purified natural products by either testing more NPs or derivatizing those already identified as drug hits, e.g., for absorption improvement; **c)** to systematically explore of plant genus or families; **d)** to develop more test to explore inhibition of virulent factors; **e)** to prepare polymers and films with bioactive natural products for in-field test of their effectivity; **f)** to define formulations to inhibit bacterial growth, that include antibiotic enhancers such as flavonoids, polyphenols or essential oils.

The mixtures of natural products and commercially available antibiotics already shown synergistic effects against opportunistic bacteria relevant in health care, food and plant industries, and several patented formulations related to toothpastes and beauty products are starting to emerge. Those trends grant further research, development and innovation in the food industry and health care systems.

Further activity in this area can led to the surge of non-traditional circular economies around certain species and even to consolidate as an additional tool to manage the resistant bacteria era.

### Acknowledgements

Authors thanks to University at Buffalo library. LN-V thanks to Chemistry Department Faculty, especially Dr. Troy Wood,; to Dr. Anthony Campagnari and Dr. Nicole Luke from Microbiology and Immunology Department, from University at Buffalo, New York,; and to Arturo Solis for sharing their expertise.

### Funding

No funding was received for this project.

### Abbreviations

Text for this section.

### Availability of data and materials

Excel base document and tables are available upon request.

#### Ethics approval and consent to participate

This study did not involve human subjects information or experiments with animal models.

#### Competing interests

The authors declare that they have no competing interests.

#### Consent for publication

All the authors consent for publication in the Future Journal of Pharmaceutical Sciences.

#### Authors' contributions

LN-V performed the literature search, statistic analysis, and prepared manuscript; SBB extracted and verified the botanical data; RAMS elaborated several tables; RC prepared several structures.

#### Authors' information

##### Author details

<sup>1</sup>Research and Development Department, Proyectos Educativos Regionales de Autoayuda, Simeon Canas Avenue 8-25a zona 2, 01002 Guatemala, Guatemala. <sup>2</sup>Research Department, Centro Universitario de Zacapa, Zacapa, Guatemala. <sup>3</sup>Facultad de Ingeniería, Universidad Rafael Landívar, Guatemala, Guatemala. <sup>4</sup>TEC, Universidad Rafael Landívar, Guatemala, Guatemala.

#### References

1. CDC: -Centers for Disease Control and Prevention. CDC and Food Safety (2021) <https://www.cdc.gov/foodsafety/cdc-and-food-safety.html>. Accessed Sept 29th, 2021.
2. [CDC]: -Center for Disease Control and Prevention. Antibiotic resistance solutions initiative (2016) <https://www.cdc.gov/drugresistance/solutions-initiative/index.html>. Accessed: Jul 25th, 2017.
3. CDC: -Center for Disease Control and Prevention. What CDC is doing: Antibiotic resistance (AR) solutions initiative (2020) <https://www.cdc.gov/drugresistance/solutions-initiative/>. Accessed Sept 29th, 2021.
4. Zhao, X., Zhao, F., Wang, J., Zhong, N.: Biofilm formation and control strategies of foodborne pathogens: food safety perspectives. *RSC Adv* **7**, 36670–83 (2017)
5. Shin, B., Park, W.: Zoonotic diseases and phytochemical medicines for microbial infections in veterinary science: Current state and future perspective. *Front Vet Sci* **5**, 166 (2018)
6. Reports and Data: Amoxicillin Market to Reach USD 4,962.6 Million by 2026 (2019) <https://www.globenewswire.com/news-release/2019/11/04/1940514/0/en/Amoxicillin-Market-To-Reach-USD-4-962-6-Million-By-2026-Reports-And-Data.html>. Accessed Sept 25th, 2021.
7. USANLM: - USA National Library of Medicine. national center for biotechnology information (2018) <https://www.ncbi.nlm.nih.gov/>. accessed jul 13th, 2018.
8. ACS: -American Chemical Society. Scifinder, a CAS solution (2018)<https://scifinder.cas.org/>. accessed jun 7th, 2018.
9. Saini, A., Singh, B., Suttee, A., Verma, S., Garg, L.K., Thakur, S.: A review on phytoconstituents: the potent synergistic approach in antimicrobial formulations. *J Pharm Res (Mohali, India)* **12**(2), 151–159 (2018)
10. Ayaz, M., Ullah, F., Sadiq, A., Ullah, F., Ovais, M., Ahmed, J., Devkota, H.P.: Synergistic interactions of phytochemicals with antimicrobial agents: Potential strategy to counteract drug resistance. *Chem-Biol Interact* **308**, 294–303 (2019). doi:10.1016/j.cbi.2019.05.050
11. Zhang, Q., Cheng, L., Zhou, X., Zou, J., Wu, H.: Small molecule inhibitors for streptococcus mutans biofilms. *Curr Org Chem* **22**(27), 2664–2670 (2018). doi:10.2174/1385272822666181128141154
12. Martelli, G., Giacomini, D.: Antibacterial and antioxidant activities for natural and synthetic dual-active compounds. *Eur J Med Chem* **158**, 91–105 (2018). doi:10.1016/j.ejmech.2018.09.009
13. Kuroda, T., Ogawa, W.: Search for novel antibacterial compounds and targets. *Yakugaku Zasshi* **137**(4), 383–388 (2017). doi:10.1248/yakushi.16-00235-3
14. Owen, L., Laird, K.: Synchronous application of antibiotics and essential oils: dual mechanisms of action as a potential solution to antibiotic resistance. *Crit Rev Microbiol* **44**(4), 414–435 (2018). doi:10.1080/1040841X.2018.1423616
15. Wagner, H., Efferth, T.: Introduction: Novel hybrid combinations containing synthetic or antibiotic drugs with plant-derived phenolic or terpenoid compounds. *Phytomedicine* **37**, 1–3 (2017). doi:10.1016/j.phymed.2017.10.020
16. Klahn, P., Broenstrup, M.: Bifunctional antimicrobial conjugates and hybrid antimicrobials. *Nat Prod Rep* **34**(7), 832–885 (2017). doi:10.1039/C7NP00006E
17. Giraudi, M., Romano, F., Aimetti, M.: An update on herbal anti-inflammatory agents in periodontal therapy. *Clin Anti-Inflammatory Anti-Allergy Drugs* **2**(1), 27–37 (2015). doi:10.2174/221270380201160517185849
18. Lazar, V., Saviuc, C.-M., Chifiriuc, M.C.: Periodontitis and periodontal disease—innovative strategies for reversing the chronic infectious and inflammatory condition by natural products. *Curr Pharm Des* **22**(2), 230–237 (2015). doi:10.2174/138161282202151221124307
19. Ahmad, A., Kaleem, M., Ahmed, Z., Shafiq, H.: Therapeutic potential of flavonoids and their mechanism of action against microbial and viral infections—a review. *Food Res Int* **77**(Part.2), 221–235 (2015). doi:10.1016/j.foodres.2015.06.021
20. Potroz, M.G., Cho, N.-J.: Natural products for the treatment of trachoma and *Chlamydia trachomatis*. *Molecules* **20**(3), 4180–4203 (2015). doi:10.3390/molecules20034180
21. Alvarez-Martinez, F.J., Barrajon-Catalan, E., Micol, V.: Tackling antibiotic resistance with compounds of natural origin: A comprehensive review. *Biomedicines* **8**(10) (2020)
22. Anand, U., Nandy, S., Mundhra, A., Das, N., Pandey, D.K., Dey, A.: A review on antimicrobial botanicals, phytochemicals and natural resistance modifying agents from apocynaceae family: Possible therapeutic approaches against multidrug resistance in pathogenic microorganisms. *Drug Resist Updat* **51**, 100695 (2020)

23. Khameneh, B., Soheili, V., Iranshahy, M., Fazly, B.B.S.: Review on plant antimicrobials: a mechanistic viewpoint. *Antimicrob Resist Infect Control* **8**, 118 (2019)
24. Wenciewicz, T.A.: Crossroads of antibiotic resistance and biosynthesis. *J Mol Biol* **431**(18), 3370–3399 (2019)
25. Lazar, V., Chifiriuc, M.C., Saviuc, C.-M.: Periodontitis and periodontal disease—innovative strategies for reversing the chronic infectious and inflammatory condition by natural products. *Curr Pharm Des* **22**(2), 230–7 (2016)
26. Yang, S.-K., Yusoff, K., Mai, C.-W., Lim, W.-M., Yap, W.-S., Lim, S.-H.E., Lai, K.-S.: Additivity vs. synergism: investigation of the additive interaction of cinnamon bark oil and meropenem in combinatory therapy. *Molecules* **22**(11), 1733–1173314 (2017). doi:10.3390/molecules22111733
27. Han, D., Zheng, Z., Wang, J.: Chinese medicine and western medicine integrated epidermis disinfecting liquid and preparation method thereof. *Faming Zhuanli Shenqing*, 107913364–20180417 (2018)
28. The Plant List, 1–12021302021
29. Rolta, R., Kumar, V., Sourirajan, A., Upadhyay, N.K., Dev, K.: Bioassay guided fractionation of rhizome extract of *Rheum emodi* wall as bio-availability enhancer of antibiotics against bacterial and fungal pathogens. *J Ethnopharmacol* **257**, 112867 (2020). doi:10.1016/j.jep.2020.112867
30. Li, F., Gong, Y., Wang, K., Yang, X., Ling, Y., Bai, L., Zheng, Y., Fu, K., Zhao, Y.: 4-(2-((1*r*,5*r*,8*as*)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethyl)furan-2(5*h*)-one with antibacterial/bacteriostatic effect and its application in preparation of antibacterial/bacteriostatic agent. *Faming Zhuanli Shenqing*, 109364063–20190222 (2019)
31. Leonida, M.D., Belbekhouche, S., Benzecry, A., Peddineni, M., Suria, A., Carbonnier, B.: Antibacterial hop extracts encapsulated in nanochitosan matrices. *Int J Biol Macromol* **120**(Part.A), 1335–1343 (2018). doi:10.1016/j.ijbiomac.2018.09.003
32. Jiang, B., Meng, L., Zhang, F., Jin, X., Zhang, G.: Enzyme-inducing effects of berberine on cytochrome p450 1a2 *in vitro* and *in vivo*. *Life Sci* **189**, 1–7 (2017). doi:10.1016/j.lfs.2017.09.011
33. Sun, J., Ruan, X., Gao, G.: Compound antibacterial drug containing tulathromycin. *Faming Zhuanli Shenqing CN 104288280 A 20150121* (2015)
34. Rodrigues-Costa, F., Slivinski, J., Ioca, L.P., Bertonha, A.F., de Felicio, R., Cunha, M.G.d., da Mata Madeira, P.V., Cauz, A.C.G., Trindade, D.M., Freire, V.F., Ropke, C.D., Gales, A., Brocchi, M., Ferreira, A.G., Gueiros-Filho, F., Trivella, D.B.B., Berlinck, R.G.S., Dessen, A.: Merulinic acid c overcomes gentamicin resistance in *Enterococcus faecium*. *Bioorg Chem* **100**, 103921 (2020). doi:10.1016/j.bioorg.2020.103921
35. Zhou, T., Li, Z., Kang, O.-H., Mun, S.-H., Seo, Y.-S., Kong, R., Shin, D.-W., Liu, X.-Q., Kwon, D.-Y.: Antimicrobial activity and synergism of ursolic acid 3-*o*- $\alpha$ -l-arabinopyranoside with oxacillin against methicillin-resistant *Staphylococcus aureus*. *Int J Mol Med* **40**(4), 1285–1293 (2017). doi:10.3892/ijmm.2017.3099
36. Aksoy, C.S., Avci, F.G., Ugurel, O.M., Atas, B., Sayar, N.A., Sariyar Akbulut, B.: Potentiating the activity of berberine for *Staphylococcus aureus* in a combinatorial treatment with thymol. *Microb Pathog* **149**, 104542 (2020). doi:10.1016/j.micpath.2020.104542
37. Guo, Q., Peng, K., Zhang, C., Cai, J.: Efficient compound bacteriostat containing berberine hydrochloride and levofloxacin for inhibiting methicillin-resistant staphylococcus aureus (mrsa) and staphylococcus aureus (sa). *Faming Zhuanli Shenqing*, 111419850–20200717 (2020)
38. Li, W.: Supramolecular nanofiber-reinforced puerarin hydrogels as drug carriers with synergistic controlled release and antibacterial properties. *J Mater Sci* **55**(15), 6669–6677 (2020). doi:10.1007/s10853-020-04455-3
39. Li, J.-h., Huang, M., Xue, Y.-h., Duan, X.-w., Zheng, H.-p.: Research on monomers activities of against *Chlamydia trachomatis in vitro* extracted from rhubarb root and rhizome and amur cork-tree. *Zhonghua Zhongyiyao Zazhi* **30**(8), 2935–2938 (2015)
40. Mehta, J., Jandaik, S., Urmila: Evaluation of phytochemicals and synergistic interaction between plant extracts and antibiotics for efflux pump inhibitory activity against *Salmonella enterica* serovar *Typhimurium* strains. *Int J Pharm Pharm Sci* **8**(10), 217–223 (2016). doi:10.22159/ijpps.2016v8i10.14062
41. Zhang, S.-c., Li, Y.-n., Wei, X.-x., Guo, D.-l., Liu, Y., Zhao, Y., Liu, Y.-x.: Anti-bacterial effects of ingredients of jingwanhong prescription against *Candida albicans in vitro*. *Zhongguo Shiyang Fangjixue Zazhi* **21**(19), 111–115 (2015). doi:10.13422/j.cnki.syfjx.2015190111
42. Britton, E.R., Kellogg, J.J., Cech, N.B., Kvalheim, O.M.: Biochemometrics to identify synergists and additives from botanical medicines: A case study with *Hydrastis canadensis* (goldenseal). *J Nat Prod* **81**(3), 484–493 (2018)
43. Sun, Z.-L., Sun, S.-C., He, J.-M., Lan, J.-E., Gibbons, S., Mu, Q.: Synergism of sophoraflavanone g with norfloxacin against effluxing antibiotic-resistant *Staphylococcus aureus*. *Int J Antimicrob Agents* **56**(3), 106098 (2020). doi:10.1016/j.ijantimicag.2020.106098
44. Yu, H., Wang, Y., Wang, X., Guo, J., Wang, H., Zhang, H., Du, F.: Jatrorrhizine suppresses the antimicrobial resistance of methicillin-resistant *Staphylococcus aureus*. *Exp Ther Med* **18**(5), 3715–3722 (2019). doi:10.3892/etm.2019.8034
45. He, J.-M., Sun, S.-C., Sun, Z.-L., Chen, J.-T., Mu, Q.: Isovalerylshikonin, a new resistance-modifying agent from *Arnebia euchroma*, suppresses antimicrobial resistance of drug-resistant *Staphylococcus aureus*. *Int J Antimicrob Agents* **53**(1), 70–73 (2019). doi:10.1016/j.ijantimicag.2018.08.021
46. Xie, Y., Ma, J., Qin, X., Li, Q., Ju, J.: Identification and utilization of two important transporters: Sgvt1 and sgvt2, for griseoviridin and viridogrisein biosynthesis in *Streptomyces griseoviridis*. *Microb Cell Fact* **16**, 177–117710 (2017). doi:10.1186/s12934-017-0792-8
47. Priyadharshini, R., Sangeetha, D., Udhaya, V., Suseela, M.R., Thummala, H.: Synergistic antibacterial activity of *Terminalia chebula*, *Vitis vinifera* and *Punica granatum* seed extracts against certain human pathogenic bacteria of clinical source. *Elixir Int J* (Dec), 44018–44023 (2016)
48. Ebrahimi, A., Moazami, B., Mahzoonieh, M.R., Lotfalian, S.: Antibacterial and ciprofloxacin -potentiation activities of *Berberis vulgaris* l. root extracts against some gram-negative pathogenic bacteria. *Adv Herb Med* **2**(1), 20–25 (2016)

49. Sun, Z.-L., He, J.-M., Wang, S.-Y., Ma, R., Khondkar, P., Kaatz, G.W., Gibbons, S., Mu, Q.: Benzocyclohexane oxide derivatives and neolignans from *Piper betle* inhibit efflux-related resistance in *Staphylococcus aureus*. *RSC Adv* **6**(49), 43518–43525 (2016). doi:10.1039/C6RA10199B
50. Tambat, R., Jangra, M., Mahey, N., Chandal, N., Kaur, M., Nandanwar, H., Chaudhary, S., Raje, M., Verma, D.K., Thakur, K.G., Jachak, S., Khatri, N.: Microbe-derived indole metabolite demonstrates potent multidrug efflux pump inhibition in *Staphylococcus aureus*. *Front Microbiol* **10**, 2153 (2019)
51. Skalweit, M.J., Li, M.: Bulgecin A as a beta-lactam enhancer for carbapenem-resistant *Pseudomonas aeruginosa* and carbapenem-resistant *Acinetobacter baumannii* clinical isolates containing various resistance mechanisms. *Drug Des Devel Ther* **10**, 3013–3020 (2016)
52. Lan, J.-E., Li, X.-J., Zhu, X.-F., Sun, Z.-L., He, J.-M., Zloh, M., Gibbons, S., Mu, Q.: Flavonoids from *Artemisia rupestris* and their synergistic antibacterial effects on drug-resistant *Staphylococcus aureus*. *Nat Prod Res* **35**(11), 1881–1886 (2021). doi:10.1080/14786419.2019.1639182
53. Miladi, H., Zmantar, T., Kouidhi, B., Al Qurashi, Y.M.A., Bakrouf, A., Chaabouni, Y., Mahdouani, K., Chaieb, K.: Synergistic effect of eugenol, carvacrol, thymol, p-cymene and gamma-terpinene on inhibition of drug resistance and biofilm formation of oral bacteria. *Microb Pathog* **112**, 156–163 (2017). doi:10.1016/j.micpath.2017.09.057
54. WHO]-World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed (2017) <http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/>. Accessed Nov 6, 2017.
55. CDC: - Center for Disease Control and Prevention. Antibiotic resistance solutions initiative (2016) <https://www.cdc.gov/drugresistance/solutions-initiative/index.html>. Accessed Jul 25th, 2017.
56. [TWH]-The White House: The White House. National Action Plan for Combating Antibiotic-resistant Bacteria. Addressing policy recommendations of the President's Council of Advisors on Science and Technology, p. 63, Washington, DC (2015)
57. Pendleton, J.N., Gorman, S.P., Gilmore, B.F.: Clinical relevance of the escape pathogens. *Expert Rev Anti-Infective Ther* **11**(3), 297–308 (2013). <https://www.ncbi.nlm.nih.gov/pubmed/23458769>
58. Tang, M., Zhang, Q.: Danshao anti-inflammatory liquid combined with levofloxacin preventing sequelae of pelvic inflammatory disease. *Liaoning Zhongyi Zazhi* **43**(3), 557–559 (2016). doi:10.13192/j.issn.1000-1719.2016.03.041
59. Yuan, Y., Wu, C., Zhang, R., Zhang, L., Li, Y.: A clinical observation of integrated chinese and western medicine in treatment of 76 cases of infantile cough variant asthma. *Shijie Zhongyiyao* **11**(4), 629–631 (2016). doi:10.3969/j.issn.1673-7202.2016.04.015
60. Wang, X.: Observation on effect of integrated traditional chinese and western medicine on preventing nosocomial infection after cesarean section. *Zhongguo Zhongyiyao Keji* **23**(5), 617 (2016)
61. Tian, X.: Clinical observation on treatment of 35 cases of acute edema pancreatitis with octreotide and chinese herbal medicine. *Zhongguo Zhongyiyao Keji* **23**(4), 474–475 (2016)
62. Chen, Y.: Clinical observation of shecao huzhang decoction combined with azithromycin in treating chronic prostatitis after std. *Zhongguo Zhongyiyao Keji* **23**(1), 98–99 (2016)
63. Zhang, H.: Clinical study on integrated treatment of traditional chinese and western medicine and nursing intervention in acute exacerbation of chronic obstructive pulmonary disease. *Xin Zhongyi* **48**(8), 260–262 (2016). doi:10.13457/j.cnki.jncm.2016.08.116
64. Lin, H., Wang, Y., Pan, Y.: Clinical efficacy of tcm combined with antibiotic treatment of chronic pelvic inflammatory disease and its effect on hemorheology level. *Zhonghua Zhongyiyao Xuekan* **33**(12), 3030–3032 (2015). doi:10.13193/j.issn.1673-7717.2015.12.060
65. Zheng, C.-x., Tan, Y.-m.: Impact of tanreqing injection combined with antibiotics on crp and pct in community acquired pneumonia patients and its therapeutic efficacy. *Biaoji Mianyi Fenxi Yu Linchuang* **22**(6), 493–495 (2015). doi:10.11748/bjmy.issn.1006-1703.2015.06.005
66. Lyu, W., Deng, Z., Sunkara, L.T., Becker, S., Robinson, K., Matts, R., Zhang, G.: High throughput screening for natural host defense peptide-inducing compounds as novel alternatives to antibiotics. *Front Cell Infect Microbiol* **8**, 191–119115 (2018). doi:10.3389/fcimb.2018.00191
67. Ding, Y.: Compounded sterilization disinfectant for sheep barn and preparation method thereof. *Faming Zhuanli Shenqing*, 108739891–20181106 (2018)
68. Wang, K., Wang, Y., Gao, J., Zhai, P., Wu, H., Yang, J., Qin, Y., Li, W.: Compound polyhexamethylene biguanide effervescent tablet and its preparation and application in treatment of cow endometritis. *Faming Zhuanli Shenqing*, 107913303–20180417 (2018)
69. Du, H., Han, L., Xu, N.: Compound liquid for bathing milk cow hoof and preparation method thereof. *Faming Zhuanli Shenqing*, 107837398–20180327 (2018)
70. Sukandar, E.Y., Kurniati, N.F., Purnama, A.B.: Anti-dysentery activity of tetracycline in combination with *Curcuma xanthorrhiza* roxb. or *Sonchus oleraceus* L. *Asian J Pharm Clin Res* **9**(6), 176–178 (2016). doi:10.22159/ajpcr.2016.v9i6.14033
71. Huang, X., Wei, X.: Medicine for treating chicken coccidiosis and preparation method thereof. *Faming Zhuanli Shenqing*, 107468697–20171215 (2017)
72. Lee, Y.-S., Kim, H.-S., Lee, J.W., Lee, D.-Y., Kim, G.-S., Kim, H.-W., Noh, G.-M., Lee, S.E., Lee, S.A., Song, O.H., Kwon, D.-y.: Potentiating activity of (+)-usnic acid on edta and sodium azide methicillin-resistant *Staphylococcus aureus*. *Saengyak Hakhoechi* **47**(2), 122–127 (2016)
73. A., N.: Compound preparation for treatment of pneumonia. *Faming Zhuanli Shenqing*, 106728404–20170531 (2017)
74. Chen, W.: Composition for controlling bacterial canker disease of *Citrus reticulata* gonggan. *Faming Zhuanli Shenqing*, 106577792–20170426 (2017)
75. Yousefi, I., Pakravan, M., Rahimi, H., Bahador, A., Farshadzadeh, Z., Haririan, I.: An investigation of electropun henna leaves extract-loaded chitosan based nanofibrous mats for skin tissue engineering. *Mater Sci Eng, C* **75**, 433–444 (2017). doi:10.1016/j.msec.2017.02.076



76. Liu, N., Zou, L., Wu, S., Zhang, P., Zhang, Y.: Application of traditional chinese medicine composition combined with antibiotics in preparing inflammation-suppressing factor medication. *Faming Zhuanli Shenqing*, 106389621–20170215 (2017)
77. A., N.: A compound medicine for poultry and livestock containing *Euphorbia humifusa*, *Rosa laevigata* and fosfomycin. *Faming Zhuanli Shenqing*, 106266052–20170104 (2017)
78. A., N.: Compound veterinary drug containing radix glycyrrhizae and ceftiofur sodium. *Faming Zhuanli Shenqing*, 106266055–20170104 (2017)
79. A., N.: Compound livestock and poultry medicine containing *Radix Glycyrrhizae*, *Cortex Cinnamomi* and norfloxacin. *Faming Zhuanli Shenqing*, 106265920–20170104 (2017)
80. A., N.: Compound veterinary drug containing *Radix glycyrrhizae* and amikacin. *Faming Zhuanli Shenqing*, 106265881–20170104 (2017)
81. A., N.: Compound livestock and poultry medicine containing *Cortex cinnamomi*, *Fructus rosae laevigatae* and amikacin. *Faming Zhuanli Shenqing*, 106266060–20170104 (2017)
82. Sun, Y., Hu, M.: A compound medicine for poultry and livestock containing *Radix glycyrrhizae*, *Cortex cinnamomi* and sulfamonomethoxine sodium. *Faming Zhuanli Shenqing*, 106265921–20170104 (2017)
83. Cui, J., Ding, R., Zhang, K., Cao, X.: Environment-friendly bactericide for controlling bacterial diseases of fruit trees and its preparation method. *Faming Zhuanli Shenqing*, 105494334–20160420 (2016)
84. Liu, C., Gao, C.: Compound herb composition capable of carrying out bacteriostatic repairing and protecting skin and preparation method thereof. *Faming Zhuanli Shenqing*, 105168672–20151223 (2015)
85. Yang, H., Li, Q., Yang, L., Sun, T., Li, X., Zhou, B., Li, J.: The competitive release kinetics and synergistic antibacterial characteristics of tea polyphenols/epsilon-poly-L-lysine hydrochloride core-shell microcapsules against *Shewanella putrefaciens*. *Int J Food Sci Technol* **55**(12), 3542–3552 (2020). doi:10.1111/ijfs.14687
86. Dutta, D., Dutta, S., Das, S.: Synergistic actions of *Rubia cordifolia* stem extract with meropenem and polymyxin b against different bacteria. *Eur J Biomed Pharm Sci* **6**(10), 243–249 (2019)
87. Malaikozhundan, B., Vinodhini, J., Kalanjiam, M.A.R., Vinotha, V., Palanisamy, S., Vijayakumar, S., Vaseeharan, B., Mariyappan, A.: High synergistic antibacterial, antibiofilm, antidiabetic and antimetabolic activity of *Withania somnifera* leaf extract-assisted zinc oxide nanoparticle. *Bioprocess Biosyst Eng* **43**(9), 1533–1547 (2020). doi:10.1007/s00449-020-02346-0
88. Zhang, F., Zhai, T., Haider, S., Liu, Y., Huang, Z.J.: Synergistic effect of chlorogenic acid and caffeic acid with fosfomycin on growth inhibition of a resistant *Listeria monocytogenes* strain. *ACS Omega* **5**(13), 7537–7544 (2020). doi:10.1021/acsomega.0c00352
89. Justino de Araujo, A.C., Freitas, P.R., Rodrigues dos Santos Barbosa, C., Muniz, D.F., Rocha, J.E., Albuquerque da Silva, A.C., Datiane de Moraes Oliveira-Tintino, C., Ribeiro-Filho, J., Everson da Silva, L., Confortin, C., Amaral, W.d., Deschamps, C., Barbosa-Filho, J.M., Ramos de Lima, N.T., Tintino, S.R., Melo Coutinho, H.D.: Gc-ms-fid characterization and antibacterial activity of the *Mikania cordifolia* essential oil and limonene against mdr strains. *Food Chem Toxicol* **136**, 111023 (2020). doi:10.1016/j.fct.2019.111023
90. Da Silva, R.S., De Oliveira, M.M.G., Silva, K.P., Da Silva Vasconcelos Rodrigues, I., Dos Santos Pinto, V., Blank, A.F., Fernandes, R.P.M.: Synergistic effect of *Cordia curassavica* jacq. essential oils association against the phytopathogen *Xanthomonas campestris* pv. *campestris*. *Environ Sci Pollut Res* **27**(4), 4376–4389 (2020). doi:10.1007/s11356-019-06631-8
91. Ghosh, T., Srivastava, S.K., Gaurav, A., Kumar, A., Kumar, P., Yadav, A.S., Pathania, R., Navani, N.K.: A combination of linalool, vitamin c, and copper synergistically triggers reactive oxygen species and dna damage and inhibits *Salmonella enterica* subsp. *enterica* serovar typhi and *Vibrio fluvialis*. *Appl Environ Microbiol* **85**(4), 02487–18102487 (2019). doi:10.1128/aem.02487-18
92. Shinde, S.S., Joshi, K.A., Patil, S., Singh, S., Kitture, R., Bellare, J., Ghosh, S.: Green synthesis of silver nanoparticles using *Gnidia glauca* and computational evaluation of synergistic potential with antimicrobial drugs. *World J Pharm Res* **7**(4), 1–16 (2018). doi:10.20959/wjpr20184-10762
93. Dzutot, J.K., Kuete, V.: Antibacterial and antibiotic-modifying activity of methanol extracts from six cameroonian food plants against multidrug-resistant enteric bacteria. *BioMed Res Int*, 1583510–1158351019 (2017). doi:10.1155/2017/1583510
94. Jiang, W., Zhao, X., Chen, L., Zhang, J., Yang, Z., Wu, Y.: An alternative antibiotic feed additive for piglet feed and its preparation method and application, piglet feed [machine translation]. *Faming Zhuanli Shenqing*, 108651737–20181016 (2018)
95. El Ouardy, K., Bouyahya, A., El Issaoui, K., Zinebi, S., Abrini, J.: Study of synergy between *Mentha pulegium* essential oil, honey and bacteriocin-like inhibitory substance e204 against *Listeria monocytogenes* cect 4032 and *Escherichia coli* k12. *Int J Curr Res Biosci Plant Biol* **3**(11), 29–35 (2016). doi:10.20546/ijcrbp.2016.311.005
96. Wang, H.: Calf chondroprotein composition and its application in product for promoting galactosis and/or preventing mazotitis. *Faming Zhuanli Shenqing*, 107929716–20180420 (2018)
97. Valli, S.A., Gowrie, S.U.: Synergistic effect of phytoconstituents in mixed sprouts- an approach towards therapeutic applications. *J Chem Pharm Res* **9**(9), 95–112 (2017)
98. Zhang, L.: Veterinary compound macleaya cordata composition preparation for treating animal diarrhea diseases. *Faming Zhuanli Shenqing*, 107625810–20180126 (2018)
99. Patra, J.K., Baek, K.-H.: Comparative study of proteasome inhibitory, synergistic antibacterial, synergistic anticandidal, and antioxidant activities of gold nanoparticles biosynthesized using fruit waste materials. *Int J Nanomed* **11**, 4691–4705 (2016). doi:10.2147/ijn.s108920
100. Saratale, G.D., Saratale, R.G., Benelli, G., Kumar, G., Pugazhendhi, A., Kim, D.-S., Shin, H.-S.: Anti-diabetic potential of silver nanoparticles synthesized with *Argyrea nervosa* leaf extract high synergistic antibacterial activity with standard antibiotics against foodborne bacteria. *J Cluster Sci* **28**(3), 1709–1727 (2017). doi:10.1007/s10876-017-1179-z
101. A., N.: A compound medicine containing cortex cinnamomi, fructus rosae laevigatae, and colistin for poultry. *Faming Zhuanli Shenqing*, 106139121–20161123 (2016)

102. A., N.: Compound medicine containing *Fructus rosae laevigatae* and mequindox for livestock and poultry. Faming Zhuanli Shenqing, 106109638–20161116 (2016)
103. Albano, M., Alves, F.C.B., Andrade, B.F.M.T., Barbosa, L.N., Pereira, A.F.M., Cunha, M.d.L.R.d.S.d., Rall, V.L.M., Fernandes Junior, A.: Antibacterial and anti-staphylococcal enterotoxin activities of phenolic compounds. *Innovative Food Sci Emerging Technol* **38**(Part\_A), 83–90 (2016). doi:10.1016/j.ifset.2016.09.003
104. Jassal, P.S., Kaur, G.: Synergistic effect of *Curcuma longa* and *Glycyrrhiza glabra* extracts with copper ions on food spoilage bacteria. *Int J Pharm Pharm Sci* **7**(10), 371–375 (2015)
105. Si, H., Hu, M., Xia, J., Liu, Z., Liu, Z., Zhao, Y., Sun, Y., Wu, Y.: A compound veterinary drug containing beta-lactam antibiotic and *Gentiana manshurica* for reversing drug resistance of bacteria to beta-lactam antibiotic. Faming Zhuanli Shenqing, 105343159–20160224 (2016)
106. Teichmann, K., Hessenberger, S., Schauerhuber, C., Pfeffer, M., Binder, E.M., Schatzmayr, G.: Additive comprising cornus species for animal feed, foodstuffs, drinking water or pharmaceutical preparations. Faming Zhuanli Shenqing, 2015010144–120150129 (2015)
107. Ghosh, T., Srivastava, S.K., Kumar, A., Kumar, P., Navani, N.K., Gaurav, A., Pathania, R., Yadav, A.S.: A combination of linalool, vitamin c, and copper synergistically triggers reactive oxygen species and dna damage and inhibits *Salmonella enterica* subsp. *enterica* serovar typhi and *Vibrio fluvialis*. *Appl Environ Microbiol* **85**(4) (2019)
108. Olajuyigbe, A.A., Olajuyigbe, O.O., Cooposamy, R.M.: Interaction of *Ziziphus mucronata* subsp. *mucronata* methanol extract and first-line antibiotics is synergistic *in vitro* through production of reactive oxygen species. *J Trop Med* **2020**, 4087394 (2020)
109. Lu, X., Wang, B., Wang, Y., Wang, H., Yan, Z.: Pharmaceutical composition for preventing decayed tooth, 105943676–20160921 (2016)
110. Ouyang, J., Wang, H., Wang, X., Li, Y., Zhou, W., Chen, P., Peng, J., Li, Y., Liu, Q., Chen, G.: Traditional chinese medicine compound toothpaste for fixing teeth, protecting gingiva, healing ulcer and blackening hair and preparation method thereof. Faming Zhuanli Shenqing, 110013452–20190716 (2019)
111. Zeng, Y., Li, L., Zhang, T., Lin, Y., Huang, M., Chen, X., Lin, T., Huang, J., Li, T., Shi, Y.: Antibacterial and antiphlogistic chinese medicinal composition and its application in preparation of oral care product. Faming Zhuanli Shenqing, 109010471–20181218 (2018)
112. Saratale, R.G., Benelli, G., Kumar, G., Kim, D.S., Saratale, G.D.: Bio-fabrication of silver nanoparticles using the leaf extract of an ancient herbal medicine, dandelion (*Taraxacum officinale*), evaluation of their antioxidant, anticancer potential, and antimicrobial activity against phytopathogens. *Environ Sci Pollut Res* **25**(11), 10392–10406 (2018). doi:10.1007/s11356-017-9581-5
113. Hu, K.: Antibacterial and antiphlogistic toothpaste and preparation method thereof. Faming Zhuanli Shenqing, 106361671–20170201 (2017)
114. Liu, C.: A chinese herbal medicines-containing health toothpaste and its making method. Faming Zhuanli Shenqing, 105411959–20160323 (2016)
115. de Oliveira Carvalho, I., Purgato, G.A., Piccolo, M.S., Pizzoli, V.R., Alves, N.D.M., Coelho, R.R., Diaz-Munoz, G.: In vitro anticariogenic and antibiofilm activities of toothpastes formulated with essential oils. *Arch Oral Biol* **117**, 104834 (2020)
116. Lv, W., Liu, C., Ye, C., Sun, J., Tan, X., Zhang, C., Qu, Q., Shi, D., Guo, S.: Structural modulation of gut microbiota during alleviation of antibiotic-associated diarrhea with herbal formula. *Int J Biol Macromol* **105**(Part\_3), 1622–1629 (2017). doi:10.1016/j.ijbiomac.2017.02.060
117. Dauda, M.L., Musa, A.M., Ilyas, M., Abdullahi, M.S., Haruna, A.: Antimicrobial potential of 2',4'-dihydroxy-4-prenyloxychalcone combined with ciprofloxacin and fluconazole. *Trop J Nat Prod Res* **3**(9), 277–281 (2019). doi:10.26538/tjnpr/v3i9.1
118. Wu, Y., Chai, B., Wang, L., Jiang, W., Hu, M., Zhao, Y., Si, H.: Antibacterial activity of total flavonoids from *Ilex rotunda* thunb. and different antibacterials on different multidrug-resistant bacteria alone or in combination. *bioRxiv, Microbiol*, 1–21 (2018)
119. Kumar, D., Gajbhiye, A., Nagda, V., Arora, A.: Characterization of root extracts of *Withania somnifera* and effect of zinc sulphate and silver nitrate on antibacterial activity against certain human pathogenic bacteria. *Int J Pharm Biol Sci* **8**(4), 682–689 (2018)
120. Macedo, I., da Silva, J.H., da Silva, P.T., Cruz, B.G., do Vale, J.P.C., dos Santos, H.S., Bandeira, P.N., de Souza, E.B., Xavier, M.R., Coutinho, H.D.M., Braz-Filho, R., Teixeira, A.M.R.: Structural and microbiological characterization of 5-hydroxy-3,7,4'-trimethoxyflavone: A flavonoid isolated from *Vitex gardneriana* schauer leaves. *Microb Drug Resist (New Rochelle, NY, USA)* **25**(3), 434–438 (2019). doi:10.1089/mdr.2018.0359
121. Costa, M.D.S., Rocha, J.E., Campina, F.F., Silva, A.R.P., Da Cruz, R.P., Pereira, R.L.S., Quintans-Junior, L.J., De Menezes, I.R.A., De S. Araujo, A.A., De Freitas, T.S., Teixeira, A.M.R., Coutinho, H.D.M.: Comparative analysis of the antibacterial and drug-modulatory effect of d-limonene alone and complexed with beta-cyclodextrin. *Eur J Pharm Sci* **128**, 158–161 (2019). doi:10.1016/j.ejps.2018.11.036
122. Bustos, P.S., Deza-Ponzio, R., Paez, P.L., Cabrera, J.L., Virgolini, M.B., Ortega, M.G.: Flavonoids as protective agents against oxidative stress induced by gentamicin in systemic circulation. potent protective activity and microbial synergism of luteolin. *Food Chem Toxicol* **118**, 294–302 (2018). doi:10.1016/j.fct.2018.05.030
123. Bernardino, A.C.S.S., Teixeira, A.M.R., de Menezes, J.E.S.A., Pinto, C.C.C., Santos, H.S., Freire, P.T.C., Coutinho, H.D.M., Sena, J. D. M., Bandeira, P.N., Braz-Filho, R.: Spectroscopic and microbiological characterization of labdane diterpene 15,16-epoxy-4-hydroxy-labda-13(16),14-dien-3,12-dione isolated from the stems of *Croton jacobinensis*. *J Mol Struct* **1147**, 335–344 (2017). doi:10.1016/j.molstruc.2017.06.084
124. Oliveira, F.d.S., Sampaio de Freitas, T., Pereira da Cruz, R., Costa, M.d.S., Pereira, R.L.S., Quintans-Junior, L.J., Andrade, T.d.A., Menezes, P.d.P., Hipolito de Sousa, B.M., Nunes, P.S., Serafini, M.R., Alencar de Menezes, I.R., Araujo, A.A.d.S., Coutinho, H.D.M.: Evaluation of the antibacterial and modulatory potential of alpha-bisabolol, beta-cyclodextrin and alpha-bisabolol/beta-cyclodextrin complex. *Biomed Pharmacother*

- 92, 1111–1118 (2017). doi:10.1016/j.biopha.2017.06.020
125. Rahi, D.K., Barwal, M.: Biosynthesis of silver nanoparticles by *Ganoderma applanatum*, evaluation of their antibacterial and antibiotic activity enhancing potential. *World J Pharm Pharm Sci* **4**(10), 1234–1247 (2015)
126. Jouda, M.M., Elbashiti, T., Masad, A., Albayoumi, M.: The antibacterial effect of some medicinal plant extracts and their synergistic effect with antibiotics. *World J Pharm Pharm Sci* **5**(2), 23–33 (2016)
127. Lim, A., Subhan, N., Jazayeri, J.A., John, G., Vanniasinkam, T., Obied, H.K.: Plant phenols as antibiotic boosters: *In vitro* interaction of olive leaf phenols with ampicillin. *Phytother Res* **30**(3), 503–509 (2016). doi:10.1002/ptr.5562
128. Rakelly de Oliveira, D., Tintino, S.R., Braga, M.F.B.M., Boligon, A.A., Athayde, M.L., Coutinho, H.D.M., Alencar de Menezes, I.R., Fachineto, R.: *In vitro* antimicrobial and modulatory activity of the natural products silymarin and silibinin. *BioMed Res Int*, 1–8 (2015). doi:10.1155/2015/292797
129. Freitas, T.S.d., Xavier, J.d.C., Pereira, R.L.S., Rocha, J.E., Muniz, D.F., da, S.P.T., Dos, S.H.S., Nogueira, C.E.S., Teixeira, A.M.R., Coutinho, H.D.M., da, H.J.P., Dos, S.H.S., Bandeira, P.N.: Direct antibacterial and antibiotic resistance modulatory activity of chalcones synthesized from the natural product 2-hydroxy-3,4,6-trimethoxyacetophenone. *FEMS Microbiol Lett* **367**(15) (2020)
130. Nafis, A., Kasrati, A., Jamali, C.A., Custodio, L., Vitalini, S., Iriti, M., Hassani, L.: A comparative study of the *in vitro* antimicrobial and synergistic effect of essential oils from *Laurus nobilis* L. and *Prunus armeniaca* L. from morocco with antimicrobial drugs: New approach for health promoting products. *Antibiotics (Basel)* **9**(4) (2020)
131. Bezerra, C.F., Camilo, C.J., Silva, M.K.d.N., Sampaio de Freitas, T., Ribeiro-Filho, J., Coutinho, H.D.M.: Vanillin selectively modulates the action of antibiotics against resistant bacteria. *Microb Pathog* **113**, 265–268 (2017). doi:10.1016/j.micpath.2017.10.052
132. Pereira, N.L.F., Aquino, P.E.A., Junior, J.G.A.S., Cristo, J.S., Vieira Filho, M.A., Moura, F.F., Ferreira, N.M.N., Silva, M.K.N., Nascimento, E.M., Correia, F.M.A., Cunha, F.A.B., Boligon, A.A., Coutinho, H.D.M., Ribeiro-Filho, J., Matias, E.F.F., Guedes, M.I.F.: Antibacterial activity and antibiotic modulating potential of the essential oil obtained from *Eugenia jambolana* in association with led lights. *J Photochem Photobiol, B* **174**, 144–149 (2017). doi:10.1016/j.jphotobiol.2017.07.027
133. Salazar, G.J.T., de Sousa, J.P., Lima, C.N.F., Lemos, I.C.S., da Silva, A.R.P., de Freitas, T.S., Coutinho, H.D.M., da Silva, L.E., do Amaral, W., Deschamps, C.: Phytochemical characterization of the *Baccharis dracunculifolia* dc (*Asteraceae*) essential oil and antibacterial activity evaluation. *Ind Crops Prod* **122**, 591–595 (2018). doi:10.1016/j.indcrop.2018.06.052
134. Tankeo, S.B., Tane, P., Kuete, V.: *In vitro* antibacterial and antibiotic potentiation activities of the methanol extracts from *Beilschmiedia acuta*, *Clausena anisata*, *Newbouldia laevis* and *Polyscias fulva* against multidrug-resistant gram negative bacteria. *BMC Complementary Altern Med* **15**, 412–141210 (2015). doi:10.1186/s12906-015-0944-5
135. Asili, J., Emami, S.A., Eynolghozat, R., Noghab, Z.S., Bazzaz, B.S.F., Sahebkar, A.: Chemical composition and *in vitro* efficacy of essential oil of seven *Artemisia* species against esbl producing multidrug-resistant *Escherichia coli*. *J Essent Oil-Bear Plants* **18**(1), 124–145 (2015). doi:10.1080/0972060X.2014.895181
136. Nishanthi, R., Paiani, P.: Green synthesis of gold nanoparticles from the rind extract of *Garcinia mangostana* and its synergistic effect with antibiotics against human pathogenic bacteria. *International Conference on Nanotechnology*, 16th, Sendai, Japan, 431–434 (2017)
137. Chen, Q., Lei, M., Qian, C., Dou, X., Lin, C., Chen, B., Qian, H.: Application of *Pseudobulbus betillae* ethanol extract in preparing polymyxin antibacterial synergist. *Faming Zhuanli Shenqing*, 109568494–20190405 (2019)
138. Coutinho, H.D.M., Oliveira-Tintino, C.D.d.M., Tintino, S.R., Pereira, R.L.S., Sampaio de Freitas, T., Pessoa da Silva, M.A., Franco, J.L., Bezerra da Cunha, F.A., Martins da Costa, J.G., Alencar de Menezes, I.R., Boligon, A.A., Teixeira da Rocha, J.B., Rocha, M.I., Sampaio dos Santos, J.F.: Toxicity against drosophila melanogaster and antiedematogenic and antimicrobial activities of *Alternanthera brasiliana* (L.) kuntze (*Amaranthaceae*). *Environ Sci Pollut Res* **25**(11), 10353–10361 (2018). doi:10.1007/s11356-017-9366-x
139. Tinrat, S., Sila-Asna, M.: Antimicrobial and synergistic effects with antibiotics of *Momordica cochinchinensis* spreng (gac fruit) aril against pathogenic bacteria. *Int J Pharm Sci Rev Res* **39**(2), 286–294 (2016)
140. Su, W., Liu, C., Zhou, Q., Li, P., Peng, W., Wang, Y.: Application of *Pithecellobium clypearia* extract in manufacture of drug for resisting extended-spectrum beta-lactamase-producing *Escherichia coli*. *Faming Zhuanli Shenqing*, 105998153–20161012 (2016)
141. Adegoke, A.A., Aiyegoro, O.A., Stenstrom, T.A.: Effect of interaction of methanol leaf extract of *Spondias mombin* (linn) and amoxicillin on some diarrheagenic *Escherichia coli*. *Trop J Pharm Res* **15**(3), 475–480 (2016). doi:10.4314/tjpr.v15i3.7
142. Dhar, S., Das, S.: Ethanolic extract of *Cinnamomum tamala* leaves enhances sensitivity zones of cephalosporins in esbl producing *Escherichia coli*. *Eur J Biomed Pharm Sci* **6**(7), 176–179 (2019)
143. Xiao, H.: Plant ointment for preventing and treating infant diaper rash and preparation method thereof. *Faming Zhuanli Shenqing*, 106266384–20170104 (2017)
144. Wang, M., Ma, B., Xue, X., Li, M., Meng, J., Luo, X., Fang, C., Hou, Z., Ni, Y.: Restoration of the antibiotic susceptibility of methicillin-resistant *Staphylococcus aureus* and extended-spectrum beta-lactamases *Escherichia coli* through combination with chelerythrine. *Microb Drug Resist* (2020)
145. Azeez, M.A., Lateef, A., Asafa, T.B., Yekeen, T.A., Akinboro, A., Oladipo, I.C., Gueguim-Kana, E.B., Beukes, L.S.: Biomedical applications of cocoa bean extract-mediated silver nanoparticles as antimicrobial, larvicidal and anticoagulant agents. *J Cluster Sci* **28**(1), 149–164 (2017). doi:10.1007/s10876-016-1055-2
146. Aneja, B., Azam, M., Alam, S., Perwez, A., Maguire, R., Yadava, U., Kavanagh, K., Daniliuc, C.G., Rizvi, M.M.A., Haq, Q.M.R., Abid, M.: Natural product-based 1,2,3-triazole/sulfonate analogues as potential chemotherapeutic agents for bacterial infections. *ACS Omega* **3**(6), 6912–6930 (2018). doi:10.1021/acsomega.8b00582
147. Tariq, M., Patole, S., Aruna, K.: Antibacterial activity of green tea (*Camellia sinensis*) leaf extract against

- metallo-beta-lactamase producing uropathogens. *Int J Adv Res Biol Sci* **2**(9), 9–15 (2015)
148. Luis, A., Duarte, A., Gominho, J., Domingues, F., Duarte, A.P.: Chemical composition, antioxidant, antibacterial and anti-quorum sensing activities of *Eucalyptus globulus* and *Eucalyptus radiata* essential oils. *Ind Crops Prod* **79**, 274–282 (2016). doi:10.1016/j.indcrop.2015.10.055
  149. Santiago, C., Pang, E.L., Lim, K.-H., Loh, H.-S., Ting, K.N.: Inhibition of penicillin-binding protein 2a (pbp2a) in methicillin resistant *Staphylococcus aureus* (mrsa) by combination of ampicillin and a bioactive fraction from *Duabanga grandiflora*. *BMC Complementary Altern Med* **15**, 1–7 (2015). doi:10.1186/s12906-015-0699-z
  150. Alhadrami, H.A., Hamed, A.A., Hassan, H.M., Belbahri, L., Rateb, M.E., Sayed, A.M.: Flavonoids as potential anti-mrsa agents through modulation of pbp2a: A computational and experimental study. *Antibiotics (Basel)* **9**(9) (2020)
  151. Santiago, C., Pang, E.L., Lim, K.-H., Loh, H.-S., Ting, K.N.: Inhibition of penicillin-binding protein 2a (pbp2a) in methicillin resistant *Staphylococcus aureus* (mrsa) by combination of ampicillin and a bioactive fraction from *Duabanga grandiflora*. *BMC Complement Altern Med* **15**, 178 (2015)
  152. Barreto, H.M., Coelho, K.M.R.N., Ferreira, J.H.L., dos Santos, B.H.C., de Abreu, A.P.L., Coutinho, H.D.M., da Silva, R.A.C., de Sousa, T.O., Cito, A.M.d.G.L., Lopes, J.A.D.: Enhancement of the antibiotic activity of aminoglycosides by extracts from *Anadenanthera colubrina* (vell.) brenan var. *cebil* against multi-drug resistant bacteria. *Nat Prod Res* **30**(11), 1289–1292 (2016). doi:10.1080/14786419.2015.1049177
  153. Deepika, M.S., Thangam, R., Sundarraj, S., Sheena, T.S., Sivasubramanian, S., Kulandaivel, J., Thirumurugan, R.: Co-delivery of diverse therapeutic compounds using peg-plga nanoparticle cargo against drug-resistant bacteria: An improved anti-biofilm strategy. *ACS Appl Bio Mater* **3**(1), 385–399 (2020). doi:10.1021/acsabm.9b00850
  154. Kumla, D., Aung, T.S., Buttachon, S., Dethoup, T., Gales, L., Pereira, J.A., Inacio, A., Costa, P.M., Lee, M., Sekeroglu, N., Silva, A.M.S., Pinto, M.M.M., Kijjoa, A.: A new dihydrochromone dimer and other secondary metabolites from cultures of the marine sponge-associated fungi *Neosartorya fennelliae* kufa 0811 and *Neosartorya tsunodae* kufc 9213. *Mar Drugs* **15**(12), 375–137517 (2017). doi:10.3390/md15120375
  155. Wang, J., Nong, X.-H., Zhang, X.-Y., Xu, X.-Y., Amin, M., Qi, S.-H.: Screening of anti-biofilm compounds from marine-derived fungi and the effects of secalonic acid d on *Staphylococcus aureus* biofilm. *J Microbiol Biotechnol* **27**(6), 1078–1089 (2017). doi:10.4014/jmb.1609.09053
  156. Roschetto, E., Masi, M., Esposito, M., Lecce, R.D., Delicato, A., Maddau, L., Calabro, V., Evente, A., Catania, M.R.: Anti-biofilm activity of the fungal phytotoxin sphaeropsidin a against clinical isolates of antibiotic-resistant bacteria. *Toxins* **12**(7), 444 (2020). doi:10.3390/toxins12070444
  157. Roschetto, E., Esposito, M., Catania, M.R., Masi, M., Di, L.R., Evidente, A., Delicato, A., Calabro, V., Maddau, L.: Anti-biofilm activity of the fungal phytotoxin sphaeropsidin a against clinical isolates of antibiotic-resistant bacteria. *Toxins (Basel)* **12**(7) (2020)
  158. Zheng, D., Huang, C., Huang, H., Zhao, Y., Khan, M.R.U., Zhao, H., Huang, L.: Antibacterial mechanism of curcumin: A review. *Chem Biodiversity* **17**(8), 2000171 (2020). doi:10.1002/cbdv.202000171
  159. Mittal, N., Tesfu, H.H., Hogan, A.M., Cardona, S.T., Sorensen, J.L.: Synthesis and antibiotic activity of novel acylated phloroglucinol compounds against methicillin-resistant *Staphylococcus aureus*. *J Antibiot* **72**(5), 253–259 (2019). doi:10.1038/s41429-019-0153-4
  160. Moreti, D.L.C., Leandro, L.F., da Silva Moraes, T., Moreira, M.R., Sola Veneziani, R.C., Ambrosio, S.R., Figueiredo Almeida Gomes, B.P., Martins, C.H.G.: *Mikania glomerata* sprengel extract and its major compound ent-kaurenoic acid display activity against bacteria present in endodontic infections. *Anaerobe* **47**, 201–208 (2017). doi:10.1016/j.anaerobe.2017.06.008
  161. Tseng, S.-P., Lin, Y.-S., Chan, M.-Y., Huang, C.-Y., Sheu, J.-H., Hung, W.-C., Lu, P.-L., Lin, L.: 5-episinuleptolide decreases the expression of the extracellular matrix in early biofilm formation of multi-drug resistant *Acinetobacter baumannii*. *Mar Drugs* **14**(8) (2016)
  162. Rubini, D., Banu, S.F., Nisha, P., Murugan, R., Thamotharan, S., Percino, M.J., Subramani, P., Nithyanand, P.: Essential oils from unexplored aromatic plants quench biofilm formation and virulence of methicillin resistant *Staphylococcus aureus*. *Microb Pathog* **122**, 162–173 (2018). doi:10.1016/j.micpath.2018.06.028
  163. Pratiwi, S.U.T., Hertiani, T.: Efficacy of massoia oil in combination with some indonesian medicinal plants oils as anti-biofilm agent towards *Candida albicans*. *Int J Pharm Sci Res* **8**(5), 2013–2025 (2017). doi:10.13040/ijpsr.0975-8232.8(5).2013-25
  164. Alabdullatif, M., Boujezza, I., Mekni, M., Taha, M., Kumaran, D., Yi, Q.-L., Landoulsi, A., Ramirez-Arcos, S.: Enhancing blood donor skin disinfection using natural oils. *Transfusion (Malden, MA, USA)* **57**(12), 2920–2927 (2017). doi:10.1111/trf.14298
  165. Koci, R.D., Stankovic-Dordevic, D.M., Dimitrijevic, M., Markovic, M.S., Miladinovic, D.L.: Potentially effective and safe anti-*helicobacter pylori* natural products: chemometric study. *Rev Chim (Bucharest, Rom)* **71**(6), 267–273 (2020). doi:10.37358/rc.20.6.8192
  166. Bialon, M., Krzysko-Lupicka, T., Pik, A., Wieczorek, P.P.: Chemical composition of herbal macerates and corresponding commercial essential oils and their effect on bacteria *Escherichia coli*. *Molecules* **22**(11), 1887–1188716 (2017). doi:10.3390/molecules22111887
  167. Sarethy, I.P., Bhatia, N., Maheshwari, N.: Antibacterial activity of plant biosurfactant extract from *Sapindus mukorossi* and *in silico* evaluation of its bioactivity. *Int J Pharm Pharm Sci* **7**(10), 419–421 (2015)
  168. Zhang, G., Jiang, C., Xie, N., Xu, Y., Liu, L., Liu, N.: Treatment with andrographolide sulfonate provides additional benefits to imipenem in a mouse model of *Klebsiella pneumoniae* pneumonia. *Biomed Pharmacother* **117**, 109065 (2019). doi:10.1016/j.biopha.2019.109065
  169. Ranjbar, R., Mohammadi, A.: Synergistic effects of combined curcumin and antibiotic in ameliorating an animal model of *Helicobacter pylori* infection. *Biomed Res (Aligarh, India)* **29**(8), 1702–1707 (2018). doi:10.4066/biomedicalresearch.29-18-277
  170. Cardoso, E.d.O., Conti, B.J., Santiago, K.B., Conte, F.L., Oliveira, L.P.G., Hernandez, R.T., Golim, M.d.A., Sforcin, J.M.: Phenolic compounds alone or in combination may be involved in propolis effects on human



- monocytes. *J Pharm Pharmacol* **69**(1), 99–108 (2017). doi:10.1111/jphp.12660
171. Austin, M.J., Hearnshaw, S.J., Mitchenall, L.A., McDermott, P.J., Howell, L.A., Maxwell, A., Searcey, M.: A natural product inspired fragment-based approach towards the development of novel anti-bacterial agents. *MedChemComm* **7**(7), 1387–1391 (2016). doi:10.1039/C6MD00229C
  172. Sayout, A., Ouarhach, A., Romane, A., Rabie, R., Dilagui, I., Sora, N.: Evaluation of antibacterial activity of *Lavandula pedunculata* subsp. *atlantica* (braun-blanc.) romo essential oil and selected terpenoids against resistant bacteria strains-structure-activity relationships. *Chem Biodivers* **17**(1), 1900496 (2020)
  173. Caesar, L.K., Nogo, S., Naphen, C.N., Cech, N.B.: Simplify: A mass spectrometry metabolomics approach to identify additives and synergists from complex mixtures. *Anal Chem* **91**(17), 11297–11305 (2019)
  174. Peng, B., Yu, C., Du, S., Liew, S.S., Mao, X., Yuan, P., Na, Z., Yao, S.Q.: Msn-on-a-chip: Cell-based screenings made possible on a small-molecule microarray of native natural products. *ChemBioChem* **19**(9), 986–996 (2018). doi:10.1002/cbic.201800101
  175. Mishra, A., Dobritsa, S.V., Crouch, M.-L., Rabenstein, J., Lee, J.X.Y., Dhakshinamoorthy, S.: Establishment and validation of a 384-well antibacterial assay amenable for high-throughput screening and combination testing. *J Microbiol Methods* **118**, 173–175 (2015). doi:10.1016/j.mimet.2015.09.019
  176. Saurav, K., Costantino, V., Venturi, V., Steindler, L.: Quorum sensing inhibitors from the sea discovered using bacterial n-acyl-homoserine lactone-based biosensors. *Mar Drugs* **15**(3), 53–15319 (2017). doi:10.3390/md15030053
  177. Gao, C.-H., Cai, P., Li, Z., Wu, Y., Huang, Q.: Co-culture of soil biofilm isolates enables the discovery of novel antibiotics. *bioRxiv, Microbiol*, 1–54 (2018). doi:10.1101/353755
  178. Dettweiler, M., Quave, C.L., Marquez, L., Bao, M., Quave, C.L.: Quantifying synergy in the bioassay-guided fractionation of natural product extracts. *PLoS One* **15**(8), 0235723 (2020)
  179. Trikas, E.D., Melidou, M., Papi, R.M., Zachariadis, G.A., Kyriakidis, D.A.: Extraction, separation and identification of anthocyanins from red wine by-product and their biological activities. *J Funct Foods* **25**, 548–558 (2016). doi:10.1016/j.jff.2016.06.033
  180. He, Y., Fu, J., Wang, Y., Yuan, Y., Meng, C., Wei, S., Xu, Y., Shang, Y., Xue, S., Yao, D., et al: A chinese medicine formulation for preventing and controlling ginger plague, and its production method. *Faming Zhuanli Shenqing*, 105123784–20151209 (2015)
  181. Wu, L., Huang, S., Pan, G., Gao, Z., Cai, D., Wu, Z.: Traditional chinese medicine composite probiotic preparation in aquaculture and preparation method thereof. *Faming Zhuanli Shenqing*, 106377569–20170208 (2017)
  182. Li, Y., Su, Y., Zhang, M., Su, X., Song, T.: Aquatic nutrient feed additive containing eucommia ulmoides powder and its preparation method. *Faming Zhuanli Shenqing*, 104489306–20150408
  183. Li, Z.: Dedicated compound fertilizer for garden uses. *Faming Zhuanli Shenqing*, 107573189–20180112 (2018)
  184. Zhao, W.: Amino acid synergistic compound fertilizer and its preparation method. *Faming Zhuanli Shenqing*, 107641017–20180130 (2018)
  185. Hu, D.: Soil-repairing agent for eliminating harmful bacteria. *Faming Zhuanli Shenqing*, 106281344–20170104 (2017)
  186. Baldwin, P.R., Reeves, A.Z., Powell, K.R., Napier, R.J., Swimm, A.I., Sun, A., Giesler, K., Bommaribus, B., Shinnick, T.M., Snyder, J.P., Liotta, D.C., Kalman, D.: Monocarbonyl analogs of curcumin inhibit growth of antibiotic sensitive and resistant strains of *Mycobacterium tuberculosis*. *Eur J Med Chem* **92**, 693–699 (2015). doi:10.1016/j.ejmech.2015.01.020

#### Figures

#### Tables

#### Additional Files

Excel file with raw data is available upon request.




























Figure 3 Summary of results of 279 reports of antibiotic synergistic assays of NPs and CAAs.


Table 1 Antibiofilm agents. a) Polyphenols, alkaloids and terpenoids, as pure compounds, that yielded antibiofilm activity. b) Essential oils and an EO's derivative, that yielded antibiofilm activity.

a) Pure compounds, antibiofilm activity

No. Antibiofilm agents (Polyphenols)	Ref.	No. Antibiofilm agents (Alkaloids and Terpenoids)	Ref.
1 Dihydrochromone 	(Kumla <i>et al.</i> , 2017)	5 Berberine 	(Aksoy <i>et al.</i> , 2020)
2 Secalonic acid D 	(Wang <i>et al.</i> , 2017)	6 Sphaeropsidine A 	(Roschetto <i>et al.</i> , 2020)
3 Curcumin 	(Zheng <i>et al.</i> , 2020)	7 Ent-kaurenic acid 	(Moreti <i>et al.</i> , 2017)
4 Acylated phloroglucinol 	(Mittal <i>et al.</i> , 2019)	8 5-Epinuleptolide 	(Tseng <i>et al.</i> , 2016)

b) Essential oils, antibiofilm activity





No. Essential oils	Structure	No. Essential oils	Structure
1 Beta-pinene 		7 Gamma terpinene 	
2 Bicyclgermacrene 		8 Geraniol 	
3 Carvacrol and thymol 		9 Germacrene D 	
4 Carvacrol-derivative 		10 Limonene 	
5 Cinnamaldehyde 		11 Mustacone 	
6 (E)-Nerolidol 		12 Spathulenol 	










**Table 2** Species of the plant extracts that yielded antibiofilm activity.

No.	Inhibition of biofilm formation by extracts from	Family	Isbio	Refs.
1	<i>Ajuga bracteosa</i> (silver nanoparticles)	Lamiaceae	1.7	(Nazer et al., 2020)
2	<i>Azadirachta indica</i>	Meliaceae	2.8	(Quelemes et al., 2015)
3	<i>Cinnamomum tamala</i>	Lauraceae	2.1	(Rubini et al., 2018)
4	<i>Copaifera duckei</i>	Leguminosae	1.9	(Goncalvez et al., 2018)
5	<i>Copaifera pubiflora</i>	Leguminosae	1.9	(da Silva et al., 2020)
6	<i>Copaifera trapezifolia</i>	Leguminosae	1.9	(Leandro et al., 2016)
7	<i>Gymnema sylvestre</i>	Apocynaceae	1	(Dineshbabu et al., 2015)
8	<i>Himatanthusdrasticus</i>	Apocynaceae	1	(Figueiredo et al., 2017)
9	<i>Leucas aspera</i>	Lamiaceae	1.7	(Dineshbabu et al., 2015)
10	<i>Mikania glomerata</i>	Compositae	1.5	(Carrara et al., 2017)
11	<i>Pogostemon heyneanus</i>	Lamiaceae	1.7	(Rubini et al., 2018)
12	<i>Scutellaria baicalensis</i>	Lamiaceae	1.7	(Leung et al., 2016)
13	<i>Vitex negundo</i>	Lamiaceae	1.7	(Dineshbabu et al., 2015)
14	<i>Withania somnifera</i>	Solanaceae	1.4	(Malaikozhundan et al., 2020)
15	Mangrove-derived endophytic fungus <i>Eurotium chevalieri</i> KUFA 0006	Fungi	NA	(Zin et al., 2017)
<b>Mixture of extracts</b>				
16	<i>Carotae fructus, Arecae semen, Granati pericarpium, Omphalia lapidescens, Coptidis rhizoma, Cyrtomii rhizoma, Meliae cortex, Platycladi cacumen, Portulacae herba, Andrographitis herba, Radix aucklandiae</i>	Several families	NA	(Campbell & Gilbert, 2019)

No.	Antibiofilm agents (Polyphenols)	Ref.
1	Dihydrochalcone 	[134]
2	Secalonic acid B 	[155]
3	Curcumin 	[158, 169, 186]
4	Acylated phloroglucinol 	[160]


No.	Antibiofilm agents (Alkaloids and Terpenoids)	Ref.
5	Berberine 	[38]
6	Sphaeropsidine A 	[156]
7	Ent-kaurenic acid 	[168]
8	5-Episinuleptolide 	[162]





## Baicalein

Root *Scutellaria baicalensis*,  
KP, Cefotaxime  
(Cai et al., 2016)




## 3-O-methyl-butylgallate

Leaves *Loranthus micranthus*,  
Inh. fatty acid saturation MT, Isoniazid  
(Rehberg et al., 2019)


## Elagephenone

St. Jhon's Wort,  
reduced virulence PA, Norfloxacin (Zhao et al., 2019)




## Carnosic acid

Rosemary and sage,  
MRSA, Gentamicin  
(Vasquez et al., 2016)




## Zeylenol

Bacteria *Piper betle*,  
SA-Nor Resistant,  
Norfloxacin  
(Sun et al., 2016)




## Clerodane diterpene

Leaves *Callicarpa americana*,  
resensitization of MRSA,  
beta-lactamics  
(Detweiller et al., 2020)




## Iodo-callophycoic acid A

Red algae *Callahycus sp.*,  
MRSA, Oxacillin  
(Lavoie et al., 2017)




## Bulgecin A

Bacteria *Paraburkholderia acidophila*,  
reduced virulence PA, beta-lactamic  
(Dik et al., 2019)



## Chelerythrine

Root *Zanthoxylum simulans*,  
MRSA, EC-ESBL, beta-lactamic  
(Wang et al., 2021)



# Assays

# Variables

# Most frequently reported

**SYN**  
**effects**  
**NPs-**  
**CAAs**  
290 reports

## NPs origin

1031 tests reported

## Strains

410 times strains were reported to be inhibited by one or more NPs-CAAs

## Antibiotics

290 times antibiotics yielded SYN effects

## Antibiofilm Act.

29 times antibiofilm agents detected

861 Plant extracts

Family: Lamiaceae

170 Purified NPs

Genus: *Lonicera*

$I_{sbio}$ : Apocynaceae, Euphorbiaceae, Rubiaceae

gram + / -

~50 % each

Phenols, flavonoids, essential oils

SA, MRSA

Hospital acquired infections

Aminoglycosides

GEN

Extracts

*Copaifera* sp., Apocynaceae, Lamiaceae

NPs

Essential oils: terpenoids phenylpropanoids

Polyphenols, alkaloids, terpenoids


$$I_{sbio} = \frac{\text{Amount of reported species}}{\text{Amount of reports}}$$


The value is directly proportional to a given family bioactivity,  $I_{sbio}=1$  is the maximum value  
The index reflects the bioactive plant diversity within the reports of given family.

Examples:


Family	# syn CADs-NPs reports	# species on those reports	$I_{sbio}$
Apocynaceae	7	7	1
Compositae	69	46	0.66

# Genera





Strain  
genera  
(318 assays)



Assays amount (%)

0

5

10

15


20


25


30


35











# Assays

Synergistic effects  
NPs  
&  
commercially available antibiotics

290 reports

# Variables

NPs origin

Strains

Antibiotics

Antibiofilm Act.

Efflux pump Inh.

# Most frequently reported

861 Plant extracts

Genera: *Lonicera*


Family: Lamiaceae

I<sub>9</sub>bio: Apocynaceae, Euphorbiaceae, Rubiaceae

170 Purified NPs

Phenols, flavonoids, essential oils

Enhancers examples:



SA, MRSA

Aminoglycosides - GEN

20 Extracts

19 NPs

Polyphenols, alkaloids, terpenoids, eos

Antibiofilm examples:

